New drugs for anti-B-cell therapy of multiple sclerosis
https://doi.org/10.14412/2074-2711-2018-1-70-73
Abstract
The review presents the data characterizing the mechanism of action of anti-B-cell therapy for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group, which has been approved for use in MS. Multicenter randomized controlled studies have shown that this drug is effective in treating both MS with exacerbations and primary progressive MS. Currently ocrelizumab is the only drug that can be used as a pathogenetic treatment for this MS course type.
About the Authors
A. N. Boyko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
N. Yu. Lashch
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
M. E. Guseva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Neurology, Neurosurgery, and Medical Genetics,
1, Ostrovityanov St., Moscow 117997
References
1. Noserworthy J, Miller D, Compston A. Disease-modifying treatments in multiple sclerosis. In: Compaston A, editor. Multiple sclerosis. 4th edition. Elsevier: 2006. P. 729-802
2. Бойко АН, Гусев ЕИ. Современные алгоритмы диагностики и лечения рассеянного склероза, основанные на индивидуальной оценке состояния пациента. Журнал неврологии и психиатрии им. С.С.Корсакова. 2017;117(2):92-106. [Boiko AN, Gusev EI. Modern algorithms for diagnosis and treatment of multiple sclerosis, based on individual assessment of the patient's condition. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2017;117(2):92-106. (In Russ.)].
3. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017 Jan;13(1):25-36. doi: 10.1038/nrneurol.2016.187. Epub 2016 Dec 9.
4. Soerensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014 Jun;27(3):246-59. doi: 10.1097/WCO.0000000000000096.
5. Haider L, Zrzavy T, Hametner S, et al. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain. Brain. 2016 Mar;139(Pt 3):807-15. doi: 10.1093/brain/awv398. Epub 2016 Feb 8.
6. Michel L, Touil H, Pikor N, et al. B Cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation. Front Immunol. 2015 Dec 24;6:636. doi: 10.3389/fimmu.2015.00636. eCollection 2015.
7. Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016 Jul;15(7):714-8. doi: 10.1016/j.autrev. 2016.03.006. Epub 2016 Mar 9.
8. Ireland SJ, Blazek M, Harp CT, et al. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity. 2012 Aug;45(5):400-14. doi: 10.3109/08916934.2012.665529. Epub 2012 Apr 18.
9. Bittner S, Ruck T, Wiendl H, et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10. 1177/1756285616666741. Epub 2016 Sep 2.
10. Montalban X, Rammohan KW, Selmaj K, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
11. Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19.
12. Kappos L, Li D, Calabresi PA, O'Connor P, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial. Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.
13. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. 14. Hauser SL, Belachew S, Kappos L. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076.
Review
For citations:
Boyko AN, Lashch NY, Guseva ME. New drugs for anti-B-cell therapy of multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):70-73. (In Russ.) https://doi.org/10.14412/2074-2711-2018-1-70-73
Views:
1111
Email this article 